Advancing pharmacologic treatment options for pharmacologic treatment options for children with epilepsy

References

• Raspall-Chaure M, Neville BG, Scott RC. The medical management of the epilepsies in children: conceptual and practical considerations. Lancet Neurol. 2008;7(1):57–69.
   PubMed Web of Science ®Google Scholar
• Arts WFM, Brouwer OF, Peters ACB, et al. Course and prognosis of childhood epilepsy: 5-year follow-up of the Dutch study of epilepsy in childhood. Brain. 2004;127:1774–1784.
   PubMed Web of Science ®Google Scholar
• Camfield PR, Camfield CS. What happens to children with epilepsy when they become adults? Some facts and opinions. Pediatr Neurol. 2014;51(1):17–23.
   PubMed Web of Science ®Google Scholar
• Picot M-C, Baldy-Moulinier M, Daurès J-P, et al. The prevalence of epilepsy and pharmacoresistant epilepsy in adults: A population-based study in a Western European country. Epilepsia. 2008;49(7):1230–1238.
   PubMed Web of Science ®Google Scholar
• Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ilae commission on therapeutic strategies. Epilepsia. 2010;51(6):1069–1077.
   PubMed Web of Science ®Google Scholar
• Gilliam FG, Fessler AJ, Baker G, et al. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology. 2004;62(1):23–27.
   PubMed Web of Science ®Google Scholar
• Berg AT, Shinnar S, Levy SR, et al. Childhood-onset epilepsy with and without preceding febrile seizures. Neurology. 1999;53(8):1742–1748.
   PubMed Web of Science ®Google Scholar
• Biton V. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007;30(4):230–240.
   PubMed Web of Science ®Google Scholar
• Ueda Y, Doi T, Tokumaru J, et al. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Mol Brain Res. 2003;116(1–2):1–6.
   PubMedGoogle Scholar
• El Desoky ES. The AMPA receptor antagonist perampanel is a new hope in the treatment for epilepsy. Fundam Clin Pharmacol. 2014;28(5):473–480.
   PubMed Web of Science ®Google Scholar
• Holder JL Jr., Wilfong AA. Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2011;12(16):2573–2581.
   PubMed Web of Science ®Google Scholar
• Guerrini R, Rosati A, Segieth J, et al. A randomized phase iii trial of adjunctive zonisamide in pediatric patients with partial epilepsy. Epilepsia. 2013;54(8):1473–1480.
   PubMed Web of Science ®Google Scholar
• Guerrini R, Rosati A, Bradshaw K, et al. Adjunctive zonisamide therapy in the long-term treatment of children with partial epilepsy: results of an open-label extension study of a phase iii, randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55(4):568–578.
   PubMed Web of Science ®Google Scholar
• Cross JH, Auvin S, Patten A, et al. Safety and tolerability of zonisamide in paediatric patients with epilepsy. Eur J Paediatric Neurol. 2014;18(6):747–758.
   PubMed Web of Science ®Google Scholar
• French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures randomized phase iii study 304. Neurology. 2012;79(6):589–596.
   PubMed Web of Science ®Google Scholar
• Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;78(18):1408–1415.
   PubMed Web of Science ®Google Scholar
• French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase iii study 305. Epilepsia. 2013;54(1):117–125.
   PubMed Web of Science ®Google Scholar
• Rosenfeld W, Conry J, Lagae L, et al. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase iii randomized clinical studies and a combined extension study. Eur J Paediatric Neurol. 2015;19(4):435–445.
   PubMed Web of Science ®Google Scholar
• Glauser TA, Ayala R, Elterman RD, et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology. 2006;66(11):1654–1660.
   PubMed Web of Science ®Google Scholar
• Elterman RD, Glauser TA, Wyllie E, et al. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neurology. 1999;52(7):1338–1344.
   PubMed Web of Science ®Google Scholar
• Matricardi S, Verrotti A, Chiarelli F, et al. Current advances in childhood absence epilepsy. Pediatr Neurol. 2014;50(3):205–212.
   PubMed Web of Science ®Google Scholar
• Glauser TA, Cnaan A, Shinnar S, et al., Childhood Absence Epilepsy S. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010;362(9):790–799.
   PubMed Web of Science ®Google Scholar
• Masur D, Shinnar S, Cnaan A, et al., Childhood Absence Epilepsy S. Pretreatment cognitive deficits and treatment effects on attention in childhood absence epilepsy. Neurology. 2013;81(18):1572–1580.
   PubMed Web of Science ®Google Scholar
• Glauser TA, Cnaan A, Shinnar S, et al., Childhood Absence Epilepsy S. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: Initial monotherapy outcomes at 12 months. Epilepsia. 2013;54(1):141–155.
   PubMed Web of Science ®Google Scholar
• Fattore C, Boniver C, Capovilla G, et al. A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. Epilepsia. 2011;52(4):802–809.
   PubMed Web of Science ®Google Scholar
• Berg AT, Levy SR, Testa FM, et al. Long-term seizure remission in childhood absence epilepsy: might initial treatment matter? Epilepsia. 2014;55(4):551–557.
   PubMed Web of Science ®Google Scholar
• Franzoni E, Matricardi S, Di Pisa V, et al. Refractory absence seizures: an italian multicenter retrospective study. Eur J Paediatric Neurol. 2015;19(6):660–664.
   PubMed Web of Science ®Google Scholar
• Ferlazzo E, Nikaronova M, Italiano D, et al. Lennox-gastaut syndrome in adulthood: clinical and EEG features. Epilepsy Res. 2010;89(2–3):271–277.
   PubMed Web of Science ®Google Scholar
• Arzimanoglou A, French J, Blume WT, et al. Lennox-gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 2009;8(1):82–93.
   PubMed Web of Science ®Google Scholar
• Hancock EC, Cross JH. Treatment of lennox-gastaut syndrome. Cochrane Database Syst Rev. 2013;2:CD003277–CD003277.
   PubMed Web of Science ®Google Scholar
• Glauser T, Kluger G, Sachdeo R, et al. Rufinamide for generalized seizures associated with lennox-gastaut syndrome. Neurology. 2008;70(21):1950–1958.
   PubMed Web of Science ®Google Scholar
• Ohtsuka Y, Yoshinaga H, Shirasaka Y, et al. Rufinamide as an adjunctive therapy for lennox-gastaut syndrome: a randomized double-blind placebo-controlled trial in japan. Epilepsy Res. 2014;108(9):1627–1636.
   PubMed Web of Science ®Google Scholar
• Ng YT, Conry JA, Drummond R, et al. Randomized, phase iii study results of clobazam in lennox-gastaut syndrome. Neurology. 2011;77(15):1473–1481.
   PubMed Web of Science ®Google Scholar
• Horacio Caraballo R, Fortini S, Fresler S, et al. Ketogenic diet in patients with lennox-gastaut syndrome. Seizure-Eur J Epilep. 2014;23(9):751–755.
   PubMed Web of Science ®Google Scholar
• Sharma S, Jain P, Gulati S, et al. Use of the modified atkins diet in lennox gastaut syndrome. J Child Neurol. 2015;30(5):576–579.
   PubMed Web of Science ®Google Scholar
• Asadi-Pooya AA, Malekmohamadi Z, Kamgarpour A, et al. Corpus callosotomy is a valuable therapeutic option for patients with lennox-gastaut syndrome and medically refractory seizures. Epilepsy Behav. 2013;29(2):285–288.
   PubMed Web of Science ®Google Scholar
• Lancman G, Virk M, Shao H, et al. Vagus nerve stimulation vs. Corpus callosotomy in the treatment of lennox-gastaut syndrome: a meta-analysis. Seizure-Eur J Epilep. 2013;22(1):3–8.
   PubMed Web of Science ®Google Scholar
• Fastenau PS, Johnson CS, Perkins SM, et al. Neuropsychological status at seizure onset in children: risk factors for early cognitive deficits. Neurology. 2009;73(7):526–534.
   PubMed Web of Science ®Google Scholar
• Ijff DM, Aldenkamp AP. Cognitive side-effects of antiepileptic drugs in children. Handb Clin Neurol. 2013;111:707–718.
   PubMedGoogle Scholar
• Eddy CM, Rickards HE, Cavanna AE. The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disord. 2011;4(6):385–407.
   PubMedGoogle Scholar
• Boshuisen K, Van Schooneveld MMJ, Uiterwaal CSPM, et al. Intelligence quotient improves after antiepileptic drug withdrawal following pediatric epilepsy surgery. Ann Neurol. 2015;78(1):104–114.
   PubMed Web of Science ®Google Scholar
• Reilly C, Atkinson P, Das KB, et al. Cognition in school-aged children with “active” epilepsy: A population-based study. J Clin Exp Neuropsychol. 2015;37(4):429–438.
   PubMed Web of Science ®Google Scholar
• Anderson M, Egunsola O, Cherrill J, et al. A prospective study of adverse drug reactions to antiepileptic drugs in children. BMJ Open. 2015;5(6):e008298.
   PubMed Web of Science ®Google Scholar
• Baca CB, Vickrey BG, Caplan R, et al. Psychiatric and medical comorbidity and quality of life outcomes in childhood-onset epilepsy. Pediatrics. 2011;128(6):E1532–E1543.
   PubMed Web of Science ®Google Scholar
• Choudhary A, Gulati S, Sagar R, et al. Behavioral comorbidity in children and adolescents with epilepsy. J Clin Neurosci. 2014;21(8):1337–1340.
   PubMed Web of Science ®Google Scholar
• Kwong KL, Lam D, Tsui S, et al. Anxiety and depression in adolescents with epilepsy. J Child Neurol. 2016;31(2):203–210.
   PubMed Web of Science ®Google Scholar
• Kwong KL, Lam D, Tsui S, et al. Attention deficit hyperactivity disorder in adolescents with epilepsy. Pediatr Neurol. 2016;57:56–63.
   PubMed Web of Science ®Google Scholar
• Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study. Neurology. 2015;85(10):866–872.
   PubMed Web of Science ®Google Scholar
• Reinisch JM, Sanders SA, Mortensen EL, et al. In-utero exposure to phenobarbital and intelligence deficits in adult men. JAMA-J Am Med Assoc. 1995;274(19):1518–1525.
   PubMed Web of Science ®Google Scholar
• Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. New England J Med. 2009;360(16):1597–1605.
   PubMed Web of Science ®Google Scholar
• Meador KJ, Baker GA, Browning N, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (nead study): a prospective observational study. Lancet Neurol. 2013;12(3):244–252.
   PubMed Web of Science ®Google Scholar
• Meador KJ, Baker GA, Browning N, et al. Effects of fetal antiepileptic drug exposure outcomes at age 4.5 years. Neurology. 2012;78(16):1207–1214.
   PubMed Web of Science ®Google Scholar
• Baker GA, Bromley RL, Briggs M, et al. Iq at 6 years after in utero exposure to antiepileptic drugs a controlled cohort study. Neurology. 2015;84(4):382–390.
   PubMed Web of Science ®Google Scholar
• Shallcross R, Bromley RL, Cheyne CP, et al. In utero exposure to levetiracetam vs valproate development and language at 3 years of age. Neurology. 2014;82(3):213–221.
   PubMed Web of Science ®Google Scholar
• Shallcross R, Bromley RL, Irwin B, et al. Child development following in utero exposure levetiracetam vs sodium valproate. Neurology. 2011;76(4):383–389.
   PubMed Web of Science ®Google Scholar
• Rheims S, Cucherat M, Arzimanoglou A, et al. Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med. 2008;5(8):1223–1237.
   Web of Science ®Google Scholar
• Löscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure-Eur J Epilep. 2011;20(5):359–368.
   PubMed Web of Science ®Google Scholar
• Simonato M, Löscher W, Cole AJ, et al. Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design. Epilepsia. 2012;53(11):1860–1867.
   PubMed Web of Science ®Google Scholar
• Błaszczyk B, Lasoń W, Czuczwar SJ. Antiepileptic drugs and adverse skin reactions: an update. Pharmacol Rep. 2015;67(3):426–434.
   PubMed Web of Science ®Google Scholar
• Tomson T, Marson A, Boon P, et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia. 2015;56(7):1006–1019.
   PubMed Web of Science ®Google Scholar
• Pellock JM, Carman WJ, Thyagarajan V, et al. Efficacy of antiepileptic drugs in adults predicts efficacy in children: a systematic review. Neurology. 2012;79(14):1482–1489.
   PubMed Web of Science ®Google Scholar
• Wilmshurst JM, Burman R, Gaillard WD, et al. Treatment of infants with epilepsy: common practices around the world. Epilepsia. 2015;56(7):1033–1046.
   PubMed Web of Science ®Google Scholar
• Dezsi G, Ozturk E, Stanic D, et al. Ethosuximide reduces epileptogenesis and behavioral comorbidity in the gaers model of genetic generalized epilepsy. Epilepsia. 2013;54(4):635–643.
   PubMed Web of Science ®Google Scholar
• Blumenfeld H, Klein JP, Schridde U, et al. Early treatment suppresses the development of spike-wave epilepsy in a rat model. Epilepsia. 2008;49(3):400–409.
   PubMed Web of Science ®Google Scholar